|
Keith T. Flaherty, MD
Director, Developmental Therapeutics
Lecturer, Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, MA
Patricia LoRusso, DO
Professor of Medicine
Chief Researcher
Director, Phase I Clinical Trials
Barbara Ann Karmanos Cancer Institute
Wayne State University
Detroit, MI
Other Expert Faculty
Paul B. Chapman, MD
Attending Physician
Melanoma/Sarcoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
Jeffery S. Weber, MD, PhD
Director, Donald A. Adam
Comprehensive Melanoma Research Center
Senior Member, Moffitt Cancer Center
Professor and Associate Chair
Department of Oncologic Sciences
University of South Florida
Tampa, FL
|
The New Paradigm for Managing Cutaneous Malignancies
Targeted and Immunotherapy
What Clinicians Want to Know
INTERACTIVE CASE-BASED LEARNING
Sheraton Chicago Hotel & Towers ~ Saturday, June 4, 2011
Registration and Dinner 6PM ~ Symposium 6:30PM to 9PM
Click here for the agenda
Each presentation is built upon two "real-life" interactive, patient case studies where participants are immediately engaged with the faculty, and are involved with patient therapy and patient management decisions via ARS throughout the symposium. And for each of the 8 patient case study sessions a faculty member will present a 15-minute didactic lecture addressing and reinforcing the evidence-based data supporting the optimal patient management decisions related to the melanoma and basal cell cancer cases. |
|
|
|
Overview |
Back to Top |
This symposium is "case-based" learning. The instructional design is one that is very highly interactive between the learner and the faculty. Each presentation begins with a patient case study, and the faculty uses the Audience Response System (ARS) for engaging participants throughout the program. The symposium will conclude with an expert panel discussion and an opportunity for participants to ask questions of the faculty.
|
|
|
| Educational Statement of Need |
Back to Top |
|
In 2010, the incidence of melanoma in the USA was an estimated 68,130 new cases with approximately 8,700 patients expected to have died of this malignancy. The majority of melanoma patients have early-stage disease that is often curable by surgically removing the malignancy from the skin but many patients require systemic therapy for their advanced or metastatic stages of this cancer. Patients with metastatic melanoma have a very poor prognosis, with a 5-year survival rate of only about 15%. No truly effective systemic therapeutic agents until very recently have been available for the treatment of advanced melanoma. However, at least two new agents are expected to be approved by the FDA in 2011 and 2012, one being a targeted, orally administered-therapy, and the other, an immunomodulatory monoclonal antibody. Thus, a need exists to help oncologists and other clinicians treating and caring for patients with melanoma better understand which patients will benefit from which of these new and very different therapeutic strategies.
Basal cell carcinoma (BCC) is the most common form of skin cancer in the USA, comprising approximately 70% of all skin cancers and affecting approximately one to two million Americans each year. There is no standard therapy for locally advanced or metastatic BCC. The survival time with metastatic BCC varies widely, but the median is approximately eight months. For improving BCC patient outcomes, a novel targeted strategy is currently in clinical development to treat inoperable BCC through inhibition of the hedgehog-signaling pathway.
Upon completion of this educational activity, participants should be able evaluate recent clinical data regarding the use of novel targeted and immunotherapeutic options under investigation for the treatment of metastatic melanoma, and similarly, evaluate data with novel targeted therapy for treating basal cell carcinoma.
|
|
|
|
|
|
This activity is designed to help medical oncologists, hematologists, surgical oncologists, and other allied health-care professionals involved in the management of patients with skin cancers, including physician assistants, nurse practitioners/nurses, pharmacists, and fellows, close Practice Gaps related to treating their patients with cutaneous malignancies. Skin cancers are managed optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to this live CME-accredited activity. |
|
|
|
|
Based on the data identified in the Needs Assessment and Physician Practice Gap Identification, the following Learning Objectives have been developed for these CME activities:
- Devise strategies for personalizing therapy to improve outcomes in patients with malignant melanoma and basal cell carcinoma.
- Describe the evidence-based data for improving overall and progression-free survival in previously untreated patients with locally advanced and metastatic melanoma using BRAF inhibition.
- Devise strategies to apply the most current scientific and clinical data supporting the utilization of CTLA-4 blockade therapy for the treatment of melanoma.
- Develop strategies to successfully manage the unique side effects or immune-related Adverse Events resulting from CTLA-4 blockade therapy.
- Compare and contrast strategies for improving survival outcomes in locally advanced and metastatic melanoma patients with targeted therapy versus immunologic therapy.
- Explain and apply the various strategies to manage therapy-related toxicities with BRAF inhibition for melanoma patients.
- Examine and apply the scientific and biologic rationale regarding inhibition of the hedgehog pathway for personalized treatment of basal cell carcinoma.
|
|
|
|
|
The Biomedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Biomedical Learning Institute designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 2 hours of Category 1 credit for attending this symposium.
Nurse Practitioners, nurses, pharmacists and Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit. |
|
|
|
| Not an official event of the 2011 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or The ASCO Cancer Foundation |
|
|
Educational Grants |
Sincere appreciation is extended to the following companies for their generous commercial support of this educational activity: |
 |
 |
|
